Perspective Net Receivables from 2010 to 2024

CATX Stock   3.69  0.22  6.34%   
Perspective Therapeutics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 986.6 K in 2024. During the period from 2010 to 2024, Perspective Therapeutics Net Receivables regression line of annual values had r-squared of  0.27 and arithmetic mean of  1,128,162. View All Fundamentals
 
Net Receivables  
First Reported
2006-03-31
Previous Quarter
999 K
Current Value
142 K
Quarterly Volatility
846.3 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 459.3 K, Total Revenue of 0.0 or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 57.93, Dividend Yield of 0.0 or PTB Ratio of 5.49. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Perspective Therapeutics Correlation against competitors.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Latest Perspective Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Perspective Therapeutics over the last few years. It is Perspective Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Perspective Net Receivables Regression Statistics

Arithmetic Mean1,128,162
Geometric Mean1,003,237
Coefficient Of Variation43.53
Mean Deviation355,814
Median1,068,656
Standard Deviation491,101
Sample Variance241.2B
Range1.8M
R-Value0.52
Mean Square Error189.4B
R-Squared0.27
Significance0.05
Slope57,133
Total Sum of Squares3.4T

Perspective Net Receivables History

2024986.6 K
20231.2 M
20221.4 M
20211.6 M
2020M
2019M
20181.2 M

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables1.2 M986.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.